1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2020, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.
Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 8, 1, 10, 3 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Post Menopausal Osteoporosis - Overview
- Post Menopausal Osteoporosis - Therapeutics Development
- Post Menopausal Osteoporosis - Therapeutics Assessment
- Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
- Post Menopausal Osteoporosis - Drug Profiles
- Post Menopausal Osteoporosis - Dormant Projects
- Post Menopausal Osteoporosis - Discontinued Products
- Post Menopausal Osteoporosis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Post Menopausal Osteoporosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Ablynx NV, H2 2020
- Post Menopausal Osteoporosis - Pipeline by AlphaMab Co Ltd, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Aryogen Pharmed Co, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Clayton Biotechnologies Inc, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Entera Bio Ltd, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Enzene Biosciences Ltd, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, H2 2020
- Post Menopausal Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H2 2020
- Post Menopausal Osteoporosis - Dormant Projects, H2 2020
- Post Menopausal Osteoporosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Post Menopausal Osteoporosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ablynx NV
- AlphaMab Co Ltd
- Amgen Inc
- Aryogen Pharmed Co
- Clayton Biotechnologies Inc
- Entera Bio Ltd
- Enteris BioPharma Inc
- Enzene Biosciences Ltd
- Epygen Biotech Pvt Ltd
- Genor BioPharma Co Ltd
- Hengenix Biotech Inc
- Hualan Biological Engineering Inc
- InSight Biopharmaceuticals Ltd
- Intas Pharmaceuticals Ltd
- Ipsen SA
- JHL Biotech Inc
- Jiangsu T-mab BioPharma Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Metabolab Inc
- Nano Intelligent Biomedical Engineering Corp
- Nanomedic Inc
- NeuClone Pty Ltd
- Paras Biopharmaceuticals Finland Oy
- Qilu Pharmaceutical Co Ltd
- Reliance Life Sciences Pvt Ltd
- Sandoz International GmbH
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Biomabs Pharmaceuticals Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Uni-Bio Science Group Ltd
- USV Pvt Ltd
